Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
  • Home
  • Current Issue
  • Early view
  • Review Series
  • Archive
  • About Us
    About Haematologica Editorial Team Our Policies Advertising Rights & Permissions Contact
  • Haematologica Award
    How to participate 2025 Winners
  • Submit a Manuscript
    Author Guidelines Reviewer Guidelines Submit and Track Manuscript Track Manuscript submitted before October 1st, 2025
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Search results are limited to:
Abstract Book of the 7th European Myeloma Network Meeting, Prague, 16-18 April 2026
Vol. 111 No. s2
Advanced filters
Search the full archive

B06 | BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE/DEXAMETHASONE IN NEWLY DIAGNOSED INTERMEDIATE-FIT AND FRAIL MULTIPLE MYELOMA: LONG-TERM EFFICACY AND SAFETY FROM THE PHASE 1/2 BELARD CLINICAL TRIAL (362 Online Views)

E. Terpos1, M. Gavriatopoulou1, I.N. Stathopoulos1, P. Malandrakis1, N. Kanellias1, M. Migkou1, F. Theodorakakou1, E. Solia1, E.E. Papaiakovou1, E. Kastritis1, M.A. Dimopoulos1|2

1 National and Kapodistrian University of Athens, Greece
2 Korea University, Seoul, South Korea
Newly diagnosed myeloma BelaRd trial Durable Disease Control.

P13 | ISATUXIMAB WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT: FINAL ANALYSIS OF A PHASE 2 STUDY BY GREEK MYELOMA STUDY GROUP (328 Online Views)

E. Terpos1, E. Kastritis1, S. Delimpasi2, K. Papathanasiou3, V. Labropoulou4, N. Kanellias1, I.N. Stathopoulos1, M. Migkou1, E. Solia1, F. Theodorakakou1, E.E. Papaiakovou1, M. Kotsopoulou5, E. Katodritou6, M. Gavriatopoulou1, M.A. Dimopoulos1|7

1 National and Kapodistrian University of Athens, Greece
2 Evangelismos Hospital, Athens, Greece
3 University of Ioannina, Greece
4 University of Patras, Medical School, Greece
5 Metaxa Cancer Hospital,Piraeus, Greece
6 Theagenio Cancer Hospital, Thessaloniki, Greece
7 Korea University, Seoul, South Korea
Greek Myeloma Study Group NDMM Isa-VRd

P17 | EARLY TREATMENT RESPONSE EVALUATION WITH WHOLE BODY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOCAL LESIONS (258 Online Views)

I. Ntanasis-Stathopoulos1, V. Koutoulidis2, M. Gavriatopoulou1, M. Douka2, P. Malandrakis1, C. Filippatos1, V. Spiliopoulou1, F. Theodorakakou1, I. Katsadouros1, I. Solia1, P. Boutsikos1, M. Migkou1, N. Kanellias1, E. Eleutherakis-Papaiakovou1, E. Kastritis1, L.A. Moulopoulos2, M.A. Dimopoulos1|3, E. Terpos1

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece
2 1st Department of Radiology, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens, Greece
3 Department of Medicine, Korea University, Seoul, South Korea
Whole-body magnetic resonance imaging NDMM Early response

P60 | TRIAL IN PROGRESS, MoMMent-3: A PROSPECTIVE, MULTINATIONAL, REAL-WORLD STUDY OF TALQUETAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (353 Online Views)

K. Weisel1, E. Kastritis2, E. Gonzalez-Garcia3, S. Gentili4, C. Renner5, P. Ferraz6, N. Francella7, S. Sitar7, J. Buyze7, N. Healy7, N.M. Suñé7, P. Moreau8, M.V. Mateos9

1 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 National and Kapodistrian University of Athens, Greece
3 University Hospital Cabueñes, Gijón, Spain
4 UOSD Ematologia Civitanova Marche AST Macerata, Civitanova Marche, Italy
5 Klinik Hirslanden, Zurich, Switzerland
6 Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, Portugal
7 Johnson & Johnson Innovative Medicine
8 Hematology Clinic, University Hospital Hotel-Dieu, Nantes, France
9 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
LocoMMotion Trial MoMMent Trial Real-world Practice

P63 | TECLISTAMY (EMN40): A PHASE 2 TRIAL OF TECLISTAMAB IN PATIENTS WITH PREVIOUSLY TREATED LIGHT-CHAIN AL AMYLOIDOSIS (335 Online Views)

M. Roussel1, E. Kastritis2, S.O. Schönland3, K.M. Kortüm4, B. Arnulf5|6, A. Jaccard1, S. Vara7, M. Doyle7, J.M. Schecter7, A. Carpinteiro8, F. Kwok9, G. Palladini10|11, M.C. Minnema12, M. Boccadoro13, P. Sonneveld14|15

1 Hematology, Centre Hospitalier Universitaire Dupuytren, Limoges, France
2 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
3 Department of Internal Medicine V, Heidelberg University Hospital, Germany
4 Department of Internal Medicine II, University Hospital of Würzburg, Germany
5 Immuno-Hematology, Saint Louis Hospital, AP-HP, Paris, France
6 Université Paris Cité, France
7 Johnson & Johnson
8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Germany
9 Department of Haematology, Westmead Hospital, Sydney, Australia
10 Department of Molecular Medicine, University of Pavia, Italy
11 Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
12 Department of Hematology, University Medical Center Utrecht, The Netherlands
13 European Myeloma Network, Italy
14 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
15 European Myeloma Network, The Netherlands
AL amyloidosis TeclistAMY (EMN40) trial

P69 | REAL-WORLD USAGE OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED WITH SECONDARY IMMUNODEFICIENCY: AN INTERIM ANALYSIS (330 Online Views)

E. Kastritis1, S. Sánchez-Ramón2, A.G. Szabo3, B. Machalinski4, A. Pérez-Montaña5, J. Chen6, B. Mc Coy7, M. Kamieniak6, S. Wietek7

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
2 Department of Clinical Immunology, Institute of Laboratory Medicine, Hospital Clínico San Carlos, Complutense University of Madrid, Spain
3 Department of Haematology, Rigshospitalet, University of Copenhagen, Denmark
4 Department of Hematology and Transplantology, Pomeranian Medical University, Szczecin, Poland
5 Hematology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
6 Takeda Development Center Americas, Inc, Cambridge, USA
7 Baxalta Innovations GmbH, a Takeda company, Vienna, Austria
Multiple Myeloma HyMMy Trial Secondary immunodeficiency
Loading...
Searching...
1 - 6 of 6 items
Navigate
  • Home
  • Current issue
  • Early view
  • Archive
  • About Haematologica
  • Editorial Team
  • Our policies
  • Contact
For Authors
  • Author Guidelines
  • Submit Manuscript
  • Track Manuscript
For Reviewers
  • Reviewer Guidelines
  • Access Your Profile
  • Access Your Tasks
For Advertisers
  • Information For Advertising
Education
  • Review Articles
  • Guidelines Articles
Privacy
  • Cookie Policy
  • Newsletter Privacy Policy
  • Privacy Policy
More
  • Rights & Permissions

  • Web design
  • Development
Copyright © 2026 by the Ferrata Storti Foundation | Web design → | Development →
ISSN 0390-6078 print | ISSN 1592-8721 online